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Background: Topiramate is an antiepileptic drug that has been approved
for migraine prophylaxis. Despite appropriate efﬁcacy for migraine pro-
phylaxis, some patients cannot tolerate its adverse effects. The aim of this
study was to compare the efﬁcacy of zonisamide, another antiepileptic
drug, with topiramate in decreasing the frequency and severity of migraine
attacks to determine whether it could be used as an alternative for non-
compliant patients to topiramate.
Methods: Eighty patients, recruited from referred migraineurs to our
neurology clinic, who met the diagnosis and inclusion criteria were al-
located randomly to group A (50-mg/d zonisamide, gradually titrated up
to 200 mg/d) and group B (25-mg/d topiramate, gradually titrated up to
100 mg/d). Each patient was followed for 12 weeks and was assessed
at entrance, in the fourth week and twelfth week for frequency of attacks,
headache severity, need for acute medication, migraine disability assess-
ment score, and adverse effects. A P G 0.05 was considered as the level of
signiﬁcant difference in all tests.
Results: Both drugs caused a signiﬁcant decrease in frequency, severity,
need for acute medication in migraine attacks, and migraine disability
assessment score (P G 0.05). Except headache severity that was reduced
signiﬁcantly better by zonisamide (P G 0.008), there were no signiﬁcant
difference between the 2 groups in other items. Except for 2 cases of
intolerable paresthesia, both drugs were tolerated well during the study.
Conclusion: Our results indicated that zonisamide is as effective as
topiramate in migraine prophylaxis and can be considered as an alter-
native treatment when topiramate is not tolerated well.
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M igraine is one of the most common primary headaches,with an estimated prevalence of 18.2% in women and
6.5% in men.1 Its nature of sustaining for several hours and
repeating multiple times in a month, in severe forms, makes it a
disabling headache. Absence from school and work or at least
reduction of functional ability is common in migraineurs and
leads to decreased social and economical productivity.2 There-
fore, a successful and easy-to-tolerate prophylactic treatment
can increase the quality of life and reduce the need for acute
medication and its relevant costs by decreasing the frequency
and severity of migraine attacks and increasing the probability
of response to symptomatic therapy.3,4 Selection of a prophylac-
tic regimen is dependent on the type of headache, drug efﬁcacy,
adverse effects, and patient’s tolerance. Among prophylactic regi-
mens, anticonvulsants are widely used.5 Topiramate is an anti-
epileptic drug and an effective migraine prophylactic drug6,7 that
has been approved for migraine prophylaxis by the Food and Drug
Administration (FDA) in 2004.8 By blocking voltage-activated
sodium and calcium channels, inhibiting of excitatory effect of
glutamate and facilitating of inhibitory effect of F-aminobutyric
acid, topiramate reduces cortical hyperexcitability and modulates
nociception.9 According to 2 large randomized, double-blind,
placebo-controlled clinical trials, the best result would be achieved
at the 100-mg/d dosage.6,7 Zonisamide is another antiepilep-
tic drug that not only has a similar effect on the glutamate and
F-aminobutyric acid neurotransmitters as well as sodium and cal-
cium channels but also reduces nitric oxide (NO) production and
scavenges NO free radicals.10,11 Considering their similar mecha-
nism of action, it seems that zonisamide can be effective in mi-
graine prophylaxis as topiramate. Few uncontrolled studies done
to evaluate the efﬁcacy of zonisamide in migraine prophylaxis
especially in refractory cases conﬁrmed that it could be effective
in prophylaxis of migraine headache.12Y17 However, controlled
trial to compare zonisamide with placebo or another approved drug
by FDAwas not performed up to now.
In this study, we compared zonisamide with topiramate in
migraine prophylaxis by evaluating their effect on frequency and
intensity of migraine headaches, need for acute medication, and
headache-induced disability by measuring migraine disability
assessment (MIDAS) questionnaire score.
METHODS
Study Design
This study was a single-center, randomized, double-blind
clinical trial. Subjects were recruited among referrals to our
neurology clinic that met both international headache society
criteria for diagnosis of migraine headache and our inclusion
criteria and gave a personal consent for participating in the study.
Except one member of trial team (F.A.), who did not con-
tribute in outcome rating, other participants (ie, all active
assessors and patients) were completely blinded about the groups
that patients were allocated. Applied dosage form of both drugs
was capsule, and to ensure allocation concealment, an indepen-
dent pharmacist packaged the drugs into numbered containers
that were dispensed on the day of randomization. The dosages of
drugs were elevated subsequently to the ultimate dose of 200mg/d
of zonisamide and 100 mg/d of topiramate within 1 month of
entering the study under the supervision of an appointed trial
member (F.A.).
The study protocol was approved by university ethics review
committee and was registered in Iranian clinical trial registration
system (IRCT), representative of World Health Organization trial
registration, under ID number IRCT201011075117N1.
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The inclusion and exclusion criteria are listed below.
Inclusion Criteria
1. History of classic or common migraine that met Interna-
tional Headache Society criteria, since at least 1 year ago;
2. Migraine attack frequency between 4 and 15 times per month,
or occur less than 4 times per month but are so prolonged
and debilitating that require preventive treatment;
3. In the cases of postmenopausal women, it should be passed
at least one year from their menopause;
4. Patients should have a negative pregnancy test, and appro-
priate contraceptive method must be used during the study;
5. History of unsuccessful prophylactic treatment with one or
more of ﬁrst-line migraine prophylaxis regimens;
6. No history of topiramate or zonisamide consumption for any
cause; and
7. Written informed consent obtained from the subject.
Exclusion Criteria
1. The presence of any other primary headaches, for example,
tension headache, cluster headache, etc; and
2. The presence of any other cause of pain that needs medi-
cations regularly, for example, neuropathy, arthritis, etc.
Outcome Measures
The primary efﬁcacy end points were changes in the head-
ache frequency (number of attacks per month) and response to
treatment (good response to treatment was deﬁned as decrease in
frequency by more than 50%), headache severity (according to a
visual scale of 1Y10 points) and the times of need for acute
medication. These end points were measured at entrance, the
fourth week, and the twelfth week of drug initiation.
Secondary efﬁcacy end points were patient’s MIDAS score
that was assessed for each patient at entrance and after the third
month of drug initiation. Adverse effects of the drug and the
necessity to inform the investigators if any occurred were clar-
iﬁed to the participants. All subjects were advised to avoid
foods that precipitate headache episodes, consumption of simple
sedatives more than 2 times per week, sleep deprivation, and any
other factor suspected to exacerbate their headache.
Statistical Analysis
The data analyses were performed by Statistical Package for
Social Sciences (SPSS) version 13. Kolmogrov-Smirnov Z was
used to check whether variables are normally distributed.
Baseline variables were compared using a 2-group t test and
Mann-Whitney U test (for headache severity) for continuous
variables, and W2 test for categorical variables. For efﬁcacy
variables, comparisons were made between baseline and the end
of treatment for each group by using paired t test and sign test,
and then among 2 groups by comparing the improvement in
variables by the 2-group t test and the Mann-Whitney U test.
Improvement was calculated by numerical difference between
the baseline and the end of study for each variable. A P G 0.05
was considered the level of signiﬁcant difference in all tests.
RESULTS
Subject Flowchart
Among 130 screened patients, 80 were enrolled in the
study: 40 patients received zonisamide and the other 40 received
topiramate (Fig. 1). Finally, 75 patients completed the study,
37 in the zonisamide group and 38 in the topiramate group. Two
patients in the zonisamide group and 2 patients in the topira-
mate group were lost to follow-up owing to adverse events. One
patient in the zonisamide group was reported to be noncom-
pliant. Because change in baseline is the primary outcome, a per-
protocol analysis was done.
Baseline Characteristics
The zonisamide and topiramate groups had similar baseline
characteristics (Table 1). The age, sex, baseline headache fre-
quency, headache severity, mean of the times of need for acute
FIGURE 1. Subjects’ ﬂowchart.
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treatment, and the mean of the MIDAS score did not differ
signiﬁcantly between the groups.
Efﬁcacy Result
Primary End Points
The frequency of migraine attacks and the times of need
for acute medication were decreased signiﬁcantly in both groups
(P G 0.001) after the fourth week and the 12th week of drug
initiation (Table 2). Nevertheless, the improvement difference
between the 2 groups was not signiﬁcant (Table 3). Good re-
sponse to treatment, deﬁned as decrease in headache frequency
by more than 50%, was attained in 37.5% and 40% of the par-
ticipants in the zonisamide and the topiramate groups, respec-
tively (P = 0.81).
The score of headache severity was decreased signiﬁcantly
in both groups (Table 2), but a better improvement was achieved
in the zonisamide group in comparison to the topiramate group
(P = 0.008; Table 3).
Secondary End Point
The mean of MIDAS score in the zonisamide and topir-
amate groups before treatment were 39.9 T 9.8 and 37.4 T 10.1,
and after 3 months of treatment initiation, these were reduced
to 13.8 T 4.4 and 12.5 T 4.7, respectively (P G 0.001). How-
ever, the difference between the 2 groups was not signiﬁcant
(P = 0.404; Table 2).
Adverse Events
Reported complications in the zonisamide group were diz-
ziness, tiredness and then drowsiness, impaired concentration, par-
esthesia, and symptoms of the restless leg syndrome. One patient
left the study owing to impaired concentration, and another left
owing to unbearable restless leg syndrome. One subject left the
study because of noncompliance but did not report a special com-
plaint. The most common complication of topiramate was pares-
thesia (22.5%), and 2 patients left the study owing to intolerable
paresthesia. Other complications in the topiramate group were fa-
tigue, nausea, drowsiness, and changes in the sense of taste.No other
adverse events were reported, and both drugs were tolerated well
eventually.
DISCUSSION
Proven efﬁcacy in migraine prophylaxis are limited to some
speciﬁc classes such as A-blockers, antidepressants, calcium
channel blockers, neuroleptics, and antiepileptics.18 Whereas a
notable number of patients experience failure of treatment owing
to the drug’s adverse events,19 the choice of a regimen is limited
more when the physician should regard other important factors
such as patient’s compliance, the presence of comorbid situations,
and various headache proﬁles. Considering these facts, anti-
epileptics by appropriate pharmacologic proﬁle and less interac-
tion are regarded as effective tool especially in refractory migraine
cases.12 Although the efﬁcacy of topiramate has been showed in
reliable trials and is one of the approved preventive medications
for migraine, its use can be limited because of adverse effects in
long-term treatment. Blurred vision, intolerable paresthesia, gas-
trointestinal upset, and cognitive adverse effects are common in
long-term treatment of topiramate.20 As mentioned before, zoni-
samide has a similar mechanism of action to topiramate, but it
has the ability to control headaches that are refractory to topira-
mate.12,13 Our results are in line with previous studies that report
appropriate efﬁcacy of zonisamide in migraine prophylaxis. More-
over, we found a better control in headache severity by zonisamide
in comparison to topiramate. This advantage may be explained by
TABLE 2. Comparison of Variables With Baseline for Each
Group at Fourth Week and 12th Week
Zonisamide Topiramate
Characteristics n = 37 P* n = 38 P*
Headache Frequency (per month)
Fourth week 4.4 T 2.2 G0.001 3.9 T 1.9 G0.001
Twelfth week 3.9 T 2.0 G0.001 3.4 T 1.8 G0.001
Headache Severity
Fourth week 4.2 T 1.0 G0.001 4.8 T 1.0 G0.001
Twelfth week 3.8 T 0.7 G0.001 4.6 T 0.9 G0.001
Need for Acute Medication
Fourth week 5.2 T 2.2 G0.001 4.0 T 1.9 G0.001
Twelfth week 4.6 T 1.8 G0.001 3.3 T 1.8 G0.001
MIDAS
Twelfth week 13.8 T 4.4 G0.001 12.5 T 4.7 G0.001
Values are presented in mean T SD.
*Comparisons were made between the fourth and 12th weeks’ out-
comes with the baseline.
TABLE 3. Outcome Result Showing Improvement by
12th Week in 2 Groups
Characteristics
Zonisamide
n = 37
Topiramate
n = 38 P*
Headache frequency
improvement†
3.6 T 1.42 3.7 T 1.89 0.71
Headache severity
improvement†
2.7 T 0.79 2.2 T 0.57 0.015
MIDAS improvement† 26 T 5.9 24.9 T 6 0.40
*Comparison of improvement between the 2 groups.
†The improvement was calculated by numerical difference between
the score at baseline and the one at twelfth week. Values presented are
means T SD.
TABLE 1. Baseline Participant Characteristics
Characteristics
Zonisamide
n = 40
Topiramate
n = 40 P
Demographics
Age, y 35.5 T 9.5 33.0 T 9.2 0.227
Sex 0.785
Male 9 8
Female 31 32
History of migraine, mean, y 10.9 T 5.4 8.9 T 5.5 0.118
Average number of previous
migraine prophylactic drugs
2.9 2.8 0.114
Headache Details
Frequency per month 7.5 T 2.9 7.2 T 3.1 0.622
Severity 6.6 T 1.1 6.9 T 1.2 0.313
Need for acute medication 8.2 T 3.2 7.7 T 3.8 0.605
MIDAS 39.8 T 9.8 37.3 T 10.0 0.814
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its effect on inhibition of T-type calcium channels and scavenging
NO products.11 However, both drugs tolerated well during the
study; zonisamide, with the ability of being used as single dose in
24 hours because of longer half-life, is expected to show a better
tolerability in long-term treatment.21 As a recent observational
study conﬁrmed, responsive but intolerant patients to topiramate
could achieve acceptable migraine prophylaxis with a better com-
pliance by using zonisamide.17
Baseline disability due to migraine, according to mean of
MIDAS (Table 1), for both studied groups was categorized as
grade IV (severe) before trial initiation. After the 12th week
of treatment, both drugs caused improvement in the migraine-
associated disability to grade III (moderate; Table 3). These
partial improvements indicate that although both of them are
efﬁcient, their usage as single therapy may not provide desirable
relief from migraine-induced disability, and perhaps, these medi-
cations should be regarded as add-on therapies for prophylaxis,
at least in patients with refractory headaches.
The main limitation of previous studies was the lack of
control group. In this trial, the results conﬁrmed the efﬁcacy of
zonisamide in comparison to topiramate as control, but the
main limitation was the small size of participants. Now, it seems
that zonisamide has the appropriate pharmacological basis and
clinical background to be proposed as a suitable alternative pro-
phylactic drug for migraine. In this phase, larger-size studies are
needed to prepare the possibility of starting the approval process
for this drug.
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